Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2

Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity

(2012) DG Evans et al.   CLINICAL GENETICS

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

(2012) Matthias A. Karajannis et al.   NEURO-ONCOLOGY

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

(2012) Scott R. Plotkin et al.   OTOLOGY & NEUROTOLOGY

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

(2011) Jaishri O. Blakeley et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset

(2011) M. J. Smith et al.   JOURNAL OF MEDICAL GENETICS

A qualitative study of the impact of living with neurofibromatosis type 2

(2011) Chirag M. Patel et al.   Psychology Health & Medicine

Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service

(2010) D.G. Evans et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

ORIGINAL ARTICLE: The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36

(2010) W.J. Neary et al.   CLINICAL OTOLARYNGOLOGY

Further genotype – phenotype correlations in neurofibromatosis 2

(2009) SK Selvanathan et al.   CLINICAL GENETICS

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

(2009) Scott R. Plotkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurofibromatosis type 2 (NF2): A clinical and molecular review

(2009) D Gareth R Evans   Orphanet Journal of Rare Diseases